The evaluation of SARS-CoV-2 mutations at the early stage of the pandemic in Istanbul population.

IF 4.6 2区医学 Q1 MICROBIOLOGY Annals of Clinical Microbiology and Antimicrobials Pub Date : 2024-10-10 DOI:10.1186/s12941-024-00750-y

Yavuz Uyar, Selen Zeliha Mart Kömürcü, Yakup Artik, Nevra Pelin Cesur, Arzu Tanrıverdi, Kamuran Şanlı

{"title":"The evaluation of SARS-CoV-2 mutations at the early stage of the pandemic in Istanbul population.","authors":"Yavuz Uyar, Selen Zeliha Mart Kömürcü, Yakup Artik, Nevra Pelin Cesur, Arzu Tanrıverdi, Kamuran Şanlı","doi":"10.1186/s12941-024-00750-y","DOIUrl":null,"url":null,"abstract":"Background: Determination of SARS-CoV-2 variant is significant to prevent the spreads of COVID-19 disease.Methods: We aimed to evaluate the variants of SARS-CoV-2 rate in positive patients in Kanuni Sultan Suleyman Training and Research Hospital (KSS-TRH), Istanbul, Türkiye between 1st January and 30th November 2021 by using RT-PCR method.Results: Herein, 825,169 patients were evaluated (male:58.53% and female:41.47%) whether COVID-19 positive or not [( +):21.3% and (-):78.7%] and 175,367 patient was described as positive (53.2%-female and 46.8%-male) by RT-PCR. COVID-19 positive rate is observed highest in the 6-15- and 66-75-year age range. The frequencies were obtained as SARS-CoV-2 positive (without mutation of B.1.1.7 [B.1.1.7 (U.K), E484K, L452R, B.1.351 (S. Africa/Brazil) spike mutations] as 66.1% (n: 115,899), B.1.1.7 Variant as 23.2% (n:40,686), Delta mutation (L452R) variant as 9.8% (n:17,182), B.1.351 variant as 0.8% (n:1370) and E484K as 0.1% (n: 230). In April 2021, general SARS-CoV-2 and B.1.1.7 variant were dominantly observed. Up to July 2021, B.1.617.2 (Delta variant/ Indian variant) and E484K has been not observed. B.1.351 variant of SARS-CoV-2 has been started in February 2021 at the rarest ratio and March 2021 is the top point. September 2021 is the pick point of E484K. African/Brazil variant of SARS-CoV-2 has been started in February 2021 at the rarest ratio and March 2021 is the top point. September 2021 is the pick point of E484K. When the gender type is compared within the variants, women were found to be more prevalent in all varieties.Conclusions: The meaning of these mutations is very important to understand the transmission capacity of the COVID-19 disease, pandemic episode, and diagnosis of the virus with mutation types. Understanding the variant type is important for monitoring herd immunity and the spread of the disease.","PeriodicalId":8052,"journal":{"name":"Annals of Clinical Microbiology and Antimicrobials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11468081/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Clinical Microbiology and Antimicrobials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12941-024-00750-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Determination of SARS-CoV-2 variant is significant to prevent the spreads of COVID-19 disease.

Methods: We aimed to evaluate the variants of SARS-CoV-2 rate in positive patients in Kanuni Sultan Suleyman Training and Research Hospital (KSS-TRH), Istanbul, Türkiye between 1st January and 30th November 2021 by using RT-PCR method.

Results: Herein, 825,169 patients were evaluated (male:58.53% and female:41.47%) whether COVID-19 positive or not [( +):21.3% and (-):78.7%] and 175,367 patient was described as positive (53.2%-female and 46.8%-male) by RT-PCR. COVID-19 positive rate is observed highest in the 6-15- and 66-75-year age range. The frequencies were obtained as SARS-CoV-2 positive (without mutation of B.1.1.7 [B.1.1.7 (U.K), E484K, L452R, B.1.351 (S. Africa/Brazil) spike mutations] as 66.1% (n: 115,899), B.1.1.7 Variant as 23.2% (n:40,686), Delta mutation (L452R) variant as 9.8% (n:17,182), B.1.351 variant as 0.8% (n:1370) and E484K as 0.1% (n: 230). In April 2021, general SARS-CoV-2 and B.1.1.7 variant were dominantly observed. Up to July 2021, B.1.617.2 (Delta variant/ Indian variant) and E484K has been not observed. B.1.351 variant of SARS-CoV-2 has been started in February 2021 at the rarest ratio and March 2021 is the top point. September 2021 is the pick point of E484K. African/Brazil variant of SARS-CoV-2 has been started in February 2021 at the rarest ratio and March 2021 is the top point. September 2021 is the pick point of E484K. When the gender type is compared within the variants, women were found to be more prevalent in all varieties.

Conclusions: The meaning of these mutations is very important to understand the transmission capacity of the COVID-19 disease, pandemic episode, and diagnosis of the virus with mutation types. Understanding the variant type is important for monitoring herd immunity and the spread of the disease.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

评估伊斯坦布尔人群中 SARS-CoV-2 基因突变在大流行初期的情况。

背景确定 SARS-CoV-2 变体对预防 COVID-19 疾病的传播意义重大：我们的目的是采用 RT-PCR 方法评估 2021 年 1 月 1 日至 11 月 30 日期间土耳其伊斯坦布尔卡努尼苏丹苏莱曼培训与研究医院（KSS-TRH）阳性患者的 SARS-CoV-2 变异率：其中，825 169 名患者（男性占 58.53%，女性占 41.47%）接受了 COVID-19 阳性与否的评估[（+）：21.3%，（-）：78.7%]，175 367 名患者通过 RT-PCR 被描述为阳性（女性占 53.2%，男性占 46.8%）。在 6-15 岁和 66-75 岁年龄段中，COVID-19 阳性率最高。SARS-CoV-2阳性（无B.1.1.7变异[B.1.1.7（英国），E484K，L452R，B.1.351（南非/巴西）尖峰变异]的频率为 66.1%（n：115 899），B.1.1.7 变异的频率为 23.1%（n：115 899），B.1.351（南非/巴西）尖峰变异的频率为 23.1%（n：115 899）。.1.7变异为23.2%（n:40,686），Delta变异（L452R）为9.8%（n:17,182），B.1.351变异为0.8%（n:1370），E484K为0.1%（n:230）。2021 年 4 月，SARS-CoV-2 和 B.1.1.7 变体占主导地位。截至 2021 年 7 月，未发现 B.1.617.2（Delta 变种/印度变种）和 E484K。SARS-CoV-2 的 B.1.351 变体在 2021 年 2 月开始出现，比例最低，2021 年 3 月是最高点。2021 年 9 月是 E484K 的采样点。SARS-CoV-2 的非洲/巴西变种于 2021 年 2 月以最罕见的比例开始传播，2021 年 3 月是最高点。2021 年 9 月是 E484K 的采样点。在对变异体的性别类型进行比较时，发现女性在所有变异体中的发病率都较高：结论：这些变异的意义对于了解 COVID-19 疾病的传播能力、大流行事件和变异类型病毒的诊断非常重要。了解变异类型对于监测群体免疫和疾病传播非常重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Annals of Clinical Microbiology and Antimicrobials MICROBIOLOGY-

CiteScore

8.60

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Annals of Clinical Microbiology and Antimicrobials considers good quality, novel and international research of more than regional relevance. Research must include epidemiological and/or clinical information about isolates, and the journal covers the clinical microbiology of bacteria, viruses and fungi, as well as antimicrobial treatment of infectious diseases. Annals of Clinical Microbiology and Antimicrobials is an open access, peer-reviewed journal focusing on information concerning clinical microbiology, infectious diseases and antimicrobials. The management of infectious disease is dependent on correct diagnosis and appropriate antimicrobial treatment, and with this in mind, the journal aims to improve the communication between laboratory and clinical science in the field of clinical microbiology and antimicrobial treatment. Furthermore, the journal has no restrictions on space or access; this ensures that the journal can reach the widest possible audience.